News and Trends 15 Aug 2022 Approval for Small Pharma major depressive disorder clinical trial Small Pharma Inc. has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (MHRA) and the Regional Ethics Committee to initiate a drug interaction clinical trial in the U.K. The clinical trial will assess the interaction between serotonin reuptake inhibitors (SSRIs) and SPL026, the company’s lead N, N-dimethyltryptamine (DMT) candidate, in patients with […] August 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Relmada Therapeutics gets Fast Track designation for major depressive disorder treatment Relmada Therapeutics, Inc., a late-stage biotech company addressing diseases of the central nervous system (CNS), has been given U.S. Food and Drug Administration (FDA) Fast Track designation to REL-1017, the company’s novel NMDA receptor (NMDAR) channel blocker, as a monotherapy for the treatment of major depressive disorder (MDD). “The receipt of Fast Track Designation represents […] August 9, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Positive news from trial for drug to treat major depressive disorder A company working on treatments for people with mental health issues has had positive feedback from the development program of an anti-depressant targeting major depressive disorder (MDD). ANeuroTech has just announced that after a successful pre-Investigational New Drug Application (IND) meeting, the US Food and Drug Administration (FDA) has given positive feedback on its […] July 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email